Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Change in Cash (2019 - 2025)

Allogene Therapeutics' Change in Cash history spans 7 years, with the latest figure at -$14.5 million for Q3 2025.

  • For Q3 2025, Change in Cash rose 87.84% year-over-year to -$14.5 million; the TTM value through Sep 2025 reached -$13.4 million, up 25.45%, while the annual FY2024 figure was -$7.9 million, 137.35% down from the prior year.
  • Change in Cash for Q3 2025 was -$14.5 million at Allogene Therapeutics, down from $9.9 million in the prior quarter.
  • Across five years, Change in Cash topped out at $119.6 million in Q2 2024 and bottomed at -$119.4 million in Q3 2024.
  • The 5-year median for Change in Cash is -$13.4 million (2021), against an average of -$7.6 million.
  • The largest YoY upside for Change in Cash was 288.89% in 2023 against a maximum downside of 294.36% in 2023.
  • A 5-year view of Change in Cash shows it stood at -$15.9 million in 2021, then rose by 21.5% to -$12.5 million in 2022, then skyrocketed by 211.69% to $13.9 million in 2023, then surged by 72.4% to $24.0 million in 2024, then crashed by 160.54% to -$14.5 million in 2025.
  • Per Business Quant, the three most recent readings for ALLO's Change in Cash are -$14.5 million (Q3 2025), $9.9 million (Q2 2025), and -$32.8 million (Q1 2025).